Weeks 9 to 20: Higher Dose Side Effects As treatment progresses to 7.5mg and 10mg, each dose escalation may trigger a temporary recurrence of gastrointestinal symptoms
For some, its hot flashes and restless nights

Contraindication screening (MTC, MEN 2, GI disease) Eligibility Criteria BMI 30 kg/m BMI 27 kg/m with comorbidities (e.g., hypertension, dyslipidemia, type 2 diabetes) Documentation Medical necessity justification Informed consent Monitoring logs for safety and insurance requirements Patient Selection & Screening The foundation of safety in GLP-1 programs is rigorous screening: Medical history : focus on thyroid cancers, MEN 2, pancreatitis, gallbladder disease, gastroparesis Psychological readiness : assess for eating disorders, severe depression, or substance abuse Laboratory screening : lipase, CMP, thyroid tests (including calcitonin if indicated), HbA1c for diabetes risk Medication Selection & Dosing Strategies Available GLP-1 options: Tirzepatide dual GIP/GLP-1 action, highest average weight loss (1522.5% in trials) Semaglutide proven safety, broad insurance coverage, cardiovascular benefits (1215% weight loss) Liraglutide daily dosing flexibility Dosing principles: Always start low and titrate gradually Adjust schedules for tolerance and patient response Provide clear patient education on dosing and side effect management Comprehensive Monitoring Programs Monitoring is not optional it is essential to safety and success

Therefore, abruptly stopping phendimetrazine or phentermine may increase the risk of withdrawal symptoms, such as depression and fatigue
As these companies contemplate their public debut, Hong Kong remains an important listing venue
PAL-150 Peptide Complex (Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7)